VAERS Explorer
Back to explore

Report #2837182

Received Apr 21, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
0.3 yrs
State
MO
Recovered
Unknown
Vaccinated
Apr 9, 2025
Onset
Apr 9, 2025
Days to onset
0
Hospital days
—

Vaccines (2)

TypeNameManufacturerDoseLotRoute / Site
DTAPIPVDTAP + IPV (QUADRACEL)SANOFI PASTEURUNKU7931ABOT / LL
DTAPIPVHIBDTAP + IPV + HIB (PENTACEL)SANOFI PASTEURUNK—OT

Symptoms (2)

No adverse eventWrong product administered

Symptom narrative

she gave the wrong medication to a 4-month old patient/patient received QUADRACEL and a HIB vaccine, but the patient was supposed to receive PENTACEL, with no reported adverse event; Initial information received on 11-Apr-2025 regarding an unsolicited valid non-serious case received from a Nurse. This case involves a 4 months old female patient to whom received Diphtheria-15/Tetanus/5 Hybrid AC Pertussis/IPV (MRC5) Vaccine [Quadracel] and a hib vaccine, instead of Diphtheria/Tetanus/5 Hybrid AC Pertussis/IPV(Vero)/HIB(PRP/T) Vaccine [Pentacel (Vero)] with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included HIB vaccine (Hib) Rotavirus vaccine and Pneumococcal vaccine conj 20v (CRM197) (Prevnar 20) for Immunisation. On 09-Apr-2025, the patient received a 0.5 ml dose of suspect Diphtheria-15/Tetanus/5 Hybrid AC Pertussis/IPV (MRC5) Vaccine Suspension for injection (strength: standard, frequency: once, expiry date: 09-Nov-2025 and lot U7931AB) via intramuscular route in the left vastus lateralis as immunization instead of Pentacel with no reported adverse event (wrong product administered) (same day latency). Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Other medications

Hib; Rotavirus vaccine; Prevnar 20